Nanjing King-Friend Biochemical PharmaceuticalLtd Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Tang Yongqun

Chief executive officer

CN¥1.5m

Total compensation

CEO salary percentage	n/a
CEO tenure	4yrs
CEO ownership	n/a
Management average tenure	no data
Board average tenure	4yrs

Recent management updates

Recent updates

CEO

Tang Yongqun (47 yo)

4yrs

Tenure

CN¥1,500,000

Compensation

Mr. Tang Yongqun is Chairman & GM of Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. since May 25, 2020

Board Members

Name	Position	Tenure	Compensation	Ownership
Tang Yongqun	Chairman & GM	4yrs	CN¥1.50m	no data
Huang Xiwei	Deputy GM	4yrs	CN¥1.11m	4.38% CN¥ 968.0m
Ping Shi	Supervisor	4yrs	no data	no data
Shuzhi Xie	Independent Director	4yrs	CN¥80.00k	no data
Zuqing Liu	Chairman of the Supervisory Board	4yrs	no data	0.0093% CN¥ 2.0m
Ma Xiaoming	Supervisor	4yrs	no data	no data
Xie Juhua	Director	4yrs	no data	no data
Tian Suoqing	Director	4yrs	no data	no data
Cui Guoqing	Independent Director	4yrs	CN¥80.00k	no data

4.0yrs

Average Tenure

59yo

Average Age

Experienced Board: 603707's board of directors are considered experienced (4 years average tenure).

Nanjing King-Friend Biochemical PharmaceuticalLtd Management

Management criteria checks 2/4

Key information

Recent management updates

Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd., Annual General Meeting, May 17, 2024

Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd., Annual General Meeting, May 17, 2024

Recent updates

Price target decreased by 19% to CN¥16.32

Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd., Annual General Meeting, May 17, 2024

First quarter 2024 earnings released: EPS: CN¥0.11 (vs CN¥0.21 in 1Q 2023)

Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd., Annual General Meeting, May 17, 2024

Now 22% overvalued

Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. to Report Q1, 2024 Results on Apr 27, 2024

Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. to Report Fiscal Year 2023 Results on Apr 27, 2024

Third quarter 2023 earnings released: EPS: CN¥0.13 (vs CN¥0.18 in 3Q 2022)

Price target increased by 8.0% to CN¥21.20

Price target decreased by 9.4% to CN¥21.13

Second quarter 2023 earnings released: EPS: CN¥0.18 (vs CN¥0.17 in 2Q 2022)

Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. to Report First Half, 2023 Results on Aug 29, 2023

Consensus EPS estimates fall by 13%

Price target increased to CN¥27.52

Third quarter 2022 earnings released: EPS: CN¥0.13 (vs CN¥0.12 in 3Q 2021)

Investor sentiment improved over the past week

Price target increased to CN¥27.14

Second quarter 2022 earnings released: EPS: CN¥0.31 (vs CN¥0.33 in 2Q 2021)

Consensus EPS estimates fall by 11%

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to CN¥34.72

Third quarter 2021 earnings released: EPS CN¥0.16 (vs CN¥0.12 in 3Q 2020)

Investor sentiment improved over the past week

Second quarter 2021 earnings released: EPS CN¥0.43 (vs CN¥0.32 in 2Q 2020)

Investor sentiment improved over the past week

Price target increased to CN¥50.79

First quarter 2021 earnings released: EPS CN¥0.29 (vs CN¥0.22 in 1Q 2020)

Investor sentiment deteriorated over the past week

New 90-day high: CN¥41.96

Investor sentiment improved over the past week

New 90-day low: CN¥31.51

Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd. Subsidiary's Product Obtaining Medicine Registration Certificate for Bendamustine Hydrochloride Injection from National Medical Products Administration

New 90-day low: CN¥34.25

New 90-day low: CN¥35.95

New 90-day low: CN¥42.05

Third quarter earnings released

New 90-day low - CN¥42.77

New 90-day high - CN¥54.57

First half earnings released

CEO

Tenure

Compensation

Board Members

Average Tenure

Average Age